•Johnson & Johnson's nipocalimab, branded as IMAAVY, has been granted FDA Priority Review status.
•Phase 2/3 trials showed positive results for the drug in treating warm autoimmune hemolytic anemia, a rare condition with no current FDA-approved treatments.